Loading
NASDAQHealthcareBiotechnology
Latest quote
$16.3961
+$0.4261 · +2.67%
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Latest quote
$16.3961
+$0.4261 · +2.67%
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
35
Expensive
Sentiment
47
Mixed
Risk
44
Elevated Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Day range
Current $16.3961
52-week range
Current $16.3961
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 2.05M USD | 2.24M USD | 2.46M USD | — | — |
| Gross profit | −2.05M USD | −2.24M USD | −2.46M USD | — | — |
| Research and development | 398.33M USD | 281.41M USD | 210.76M USD | 142.76M USD | 121.31M USD |
| Selling, general, and administrative | 69.85M USD | 62.48M USD | 31.4M USD | 28.2M USD | 28.72M USD |
| Operating expenses | 466.14M USD | 341.64M USD | 239.7M USD | 170.96M USD | 150.03M USD |
| Interest income | 29.86M USD | 26.92M USD | 7.64M USD | 2.92M USD | 742K USD |
| Interest expense | 6.19M USD | — | — | 2.92M USD | — |
| Depreciation and amortization | 2.05M USD | 1.67M USD | 1.67M USD | 1.68M USD | 1.09M USD |
| Operating income | −468.18M USD | −343.89M USD | −242.16M USD | −170.96M USD | −150.03M USD |
| Net income | −446.21M USD | −317.42M USD | −235.94M USD | −168.1M USD | −149.29M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$35.20
114.69% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI133.68M0.01%2.3T USD0.03%$379.29-0.46%
State Street SPDR S&P Biotech ETFXBI71.4M0.71%10.08B USD0.35%$149.63-0.40%
iShares Russell 2000 ETFIWM64.57M0.08%78.56B USD0.19%$277.44-0.10%
Vanguard Extended Market ETFVXF48.87M0.05%95.4B USD0.05%$233.03-0.20%
Vanguard Morningstar Small-Cap ETFVB48.31M0.03%185.3B USD0.03%$287.43+0.16%
Vanguard Morningstar Small-Cap Value ETFVBR30.7M0.04%68.2B USD0.05%$233.79+0.70%
Vanguard Russell 2000 ETFVTWO22.15M0.12%18B USD0.06%$112.05-0.14%
iShares Biotechnology ETFIBB18.53M0.18%10.4B USD0.44%$200.54-1.38%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
